An August 2026 Eli Lilly news release detailed six new lawsuits against U.S. businesses over alleged black-market sales of the investigational drug retatrutide.
Detailed Allegations of Illegal Retatrutide Sales by Med Spa, Peptide Sellers, and Pharmacy
On August 12, 2026, Eli Lilly detailed six new federal lawsuits involving alleged black-market sales of retatrutide by a Med Spa, four peptide sellers, and a pharmacy. The company also called on regulators, law enforcement, online platforms, payment companies, and shipping providers to take action against the sale and distribution of products marketed as retatrutide. For Med Spa and wellness operators, the lawsuits add to existing FDA enforcement and guidance involving unapproved GLP-1 drugs, product sourcing, and federal compounding restrictions.
Six Federal Lawsuits Target Alleged Retatrutide Sales
On August 12, 2026, Eli Lilly announced six federal lawsuits against U.S. businesses it alleges sold products represented as retatrutide. The cases span federal courts in California and Texas and involve a Med Spa, a compounding pharmacy, and online peptide sellers.
The defendants include:
- Aesthetic Envy Cosmetic Centers LLC
- Astra LLC d/b/a Astra Peptides
- Legendary Peptides LLC
- Striker Pharmacy LLC
- Texas Peptides Inc.
- Lone Star Peptide Co.
Lilly characterized the products as part of an illegal market for retatrutide and alleged that some sellers marketed products as “research-use only” despite intending them for human use.
Lilly also reported that it has:
- Referred more than 200 individuals and entities to FDA, the U.S. Department of Justice, state attorneys general, law enforcement agencies, and professional licensing boards.
- Reported more than 14,000 websites, advertisements, social media posts, and product listings involving retatrutide across more than 100 countries.
The company also called on regulators, customs agencies, law enforcement, online platforms, payment companies, shipping providers, and healthcare professionals to take additional action involving the sale and distribution of retatrutide products. Per Eli Lilly, retatrutide remains in Phase 3 clinical development and has not received regulatory approval for human use. Lilly also cited FDA guidance stating that retatrutide cannot lawfully be compounded and that products marketed for human use as “research-use only” are of unknown quality and may pose health risks. The six civil lawsuits remain pending as of this reporting.
Source: Eli Lilly Retatrutide Lawsuits
According to Eli Lilly’s August 12, 2026 news release, the company filed six federal lawsuits alleging the sale of products marketed as retatrutide and detailed its broader efforts to report related activity to regulators, law enforcement agencies, professional licensing boards, and online platforms.
Compliance Considerations for Med Spa and Wellness Operators
The allegations in Lilly’s six lawsuits center on the sale and marketing of products represented as retatrutide while the drug remains investigational and unavailable for lawful consumer sale. The drug is currently in Phase 3 trials for obesity, type 2 diabetes, obstructive sleep apnea, and several related conditions. The company also alleges that some sellers used “research-use only” positioning even though the products allegedly were intended for human use.
The lawsuits raise compliance considerations involving:
- Investigational drug status
- Product legality and regulatory status
- Supplier and source representations
- Marketing and social media claims
- Drug representations about intended use
The allegations also fit within broader federal and state enforcement involving peptide and weight-loss products sold outside established drug pathways. In July 2026, a federal judge in Michigan sentenced a defendant after prosecutors reported sales of imported peptides, semaglutide, and tirzepatide through websites that marketed the products for “research purposes only.”
Enforcement activity has also extended to Med Spa advertising and prescribing practices. A May 2026 Connecticut Attorney General settlement involving Radiance Medspa addressed advertising and prescribing non-FDA-approved compounded semaglutide and tirzepatide. At the federal level, FDA warning letters issued in June 2026 also cited equivalence claims and “FDA-approved” sourcing language used in weight-loss marketing.
The pending lawsuits add a separate private-litigation development involving alleged investigational drug sales across the Med Spa, peptide, and pharmacy sectors. Operators offering weight-management services remain subject to applicable federal and state drug, compounding, prescribing, drug sourcing and distribution, and marketing requirements.
Lilly’s lawsuits allege that products represented as retatrutide were sold for human use while the drug remains investigational and unavailable for lawful consumer sale.
Key Compliance Takeaways for Med Spa and Weight-Management Services
- Verify that any drug offered for patient use is lawfully available and appropriately sourced.
- Confirm that weight-management treatment protocols align with applicable prescribing, compounding, and administration requirements.
- Review supplier claims about product identity, regulatory status, and intended use.
- Ensure marketing, social media content, and patient-facing materials accurately reflect lawful drug pathways and regulatory status.
- Document pharmacy, supplier, prescription, and product information for medications used in weight-management services.
- Follow FDA and other applicable regulatory updates involving GLP-1 drugs, peptides, and other drug products in Med Spa service offerings.
What to Watch Next
As of this reporting, Eli Lilly’s six lawsuits remain pending. Retatrutide remains investigational and in Phase 3 clinical development, with no approval for public use. Further court filings or updates from applicable regulatory agencies may provide additional context for Med Spa and wellness operators regarding retatrutide, drug sourcing, compounding restrictions, and related weight-management services.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our website.
Image Attribution: “Eli Lilly Corporate Center, Indianapolis, Indiana, USA” by Momoneymoproblemz, via Wikimedia Commons, licensed under CC BY-SA 4.0.
